Cargando…

Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease

AIMS: The aim of this study was to determine if elastin content in needle core native liver biopsies was predictive of clinical outcome in patients with chronic hepatitis C virus‐related chronic liver disease. METHODS AND RESULTS: Elastin contents in liver biopsies were determined by image analysis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kendall, Timothy J, Dolman, Grace E, Duff, Catherine M, Paish, Emma C, Zaitoun, Abed, Irving, William, Fallowfield, Jonathan A, Guha, Indra N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033111/
https://www.ncbi.nlm.nih.gov/pubmed/29464815
http://dx.doi.org/10.1111/his.13499
_version_ 1783337637733466112
author Kendall, Timothy J
Dolman, Grace E
Duff, Catherine M
Paish, Emma C
Zaitoun, Abed
Irving, William
Fallowfield, Jonathan A
Guha, Indra N
author_facet Kendall, Timothy J
Dolman, Grace E
Duff, Catherine M
Paish, Emma C
Zaitoun, Abed
Irving, William
Fallowfield, Jonathan A
Guha, Indra N
author_sort Kendall, Timothy J
collection PubMed
description AIMS: The aim of this study was to determine if elastin content in needle core native liver biopsies was predictive of clinical outcome in patients with chronic hepatitis C virus‐related chronic liver disease. METHODS AND RESULTS: Elastin contents in liver biopsies were determined by image analysis, technically validated in an independent centre, and correlated with outcome in patients with advanced (Ishak stage ≥5) chronic hepatitis C virus‐related chronic liver disease. Elastin was robustly quantified in an operator‐independent and laboratory‐independent manner, with very strong correlation of elastin staining measured with two methods of image classification (r (s) = 0.873, P < 0.00001). Elastin content (but not absolute scar content or Ishak stage) was predictive for future clinical outcomes. In a cohort of patients without sustained virological response, the median hepatic elastin content was 3.4%, and 17 patients (57%) progressed to a liver‐related clinical outcome; 11 of the 15 patients (73%) with a hepatic elastin content of >3.4% progressed to a clinical outcome, as compared with only six of 15 (40%) with an elastin content of <3.4%. The difference in time to outcome was significant. CONCLUSIONS: We describe a simple and reproducible method for elastin quantification in liver biopsies that provides potentially valuable prognostic information to inform clinical management.
format Online
Article
Text
id pubmed-6033111
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60331112018-07-12 Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease Kendall, Timothy J Dolman, Grace E Duff, Catherine M Paish, Emma C Zaitoun, Abed Irving, William Fallowfield, Jonathan A Guha, Indra N Histopathology Original Articles AIMS: The aim of this study was to determine if elastin content in needle core native liver biopsies was predictive of clinical outcome in patients with chronic hepatitis C virus‐related chronic liver disease. METHODS AND RESULTS: Elastin contents in liver biopsies were determined by image analysis, technically validated in an independent centre, and correlated with outcome in patients with advanced (Ishak stage ≥5) chronic hepatitis C virus‐related chronic liver disease. Elastin was robustly quantified in an operator‐independent and laboratory‐independent manner, with very strong correlation of elastin staining measured with two methods of image classification (r (s) = 0.873, P < 0.00001). Elastin content (but not absolute scar content or Ishak stage) was predictive for future clinical outcomes. In a cohort of patients without sustained virological response, the median hepatic elastin content was 3.4%, and 17 patients (57%) progressed to a liver‐related clinical outcome; 11 of the 15 patients (73%) with a hepatic elastin content of >3.4% progressed to a clinical outcome, as compared with only six of 15 (40%) with an elastin content of <3.4%. The difference in time to outcome was significant. CONCLUSIONS: We describe a simple and reproducible method for elastin quantification in liver biopsies that provides potentially valuable prognostic information to inform clinical management. John Wiley and Sons Inc. 2018-04-16 2018-07 /pmc/articles/PMC6033111/ /pubmed/29464815 http://dx.doi.org/10.1111/his.13499 Text en © 2018 The Authors. Histopathology published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Kendall, Timothy J
Dolman, Grace E
Duff, Catherine M
Paish, Emma C
Zaitoun, Abed
Irving, William
Fallowfield, Jonathan A
Guha, Indra N
Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease
title Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease
title_full Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease
title_fullStr Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease
title_full_unstemmed Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease
title_short Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease
title_sort hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033111/
https://www.ncbi.nlm.nih.gov/pubmed/29464815
http://dx.doi.org/10.1111/his.13499
work_keys_str_mv AT kendalltimothyj hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease
AT dolmangracee hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease
AT duffcatherinem hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease
AT paishemmac hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease
AT zaitounabed hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease
AT irvingwilliam hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease
AT fallowfieldjonathana hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease
AT guhaindran hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease